Sign Out
History, signs or symptoms of significant liver impairment or injury, excluding uncomplicated polycystic liver disease.
Anuria; no clinical benefit expected.
Concomitant use with strong CYP3A inhibitors (eg, clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin).
Fluid balance, inability to autoregulate; increased risk of too-rapid correction of serum sodium, hypernatremia, and hypovolemia.
Hypersensitivity (eg, anaphylactic shock or generalized rash) to Tolvaptan or any component of the product.
Hypovolemic hyponatremia; risks associated with worsening hypovolemia (eg, hypotension and renal failure) outweigh possible benefits.
Urgent need to raise serum sodium acutely; not studied for this use.
Uncorrected urinary outflow obstruction.
Unable to sense or respond to thirst.
Uncorrected abnormal blood sodium concentrations.
Continue with Google